Hims & Hers Health (NYSE:HIMS) Insider Sells $441,532.84 in Stock

Hims & Hers Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Insider Deborah Autor sold 23,828 Hims & Hers shares for $441,532.84 under a pre-arranged Rule 10b5-1 plan, reducing her stake by 32.74% to 48,961 shares.
  • Hims & Hers reported quarterly EPS of $0.03, below the $0.06 consensus, and revenue of $890.37 million, slightly under estimates; revenue grew 48.6% year over year.
  • Shares fell 2.5% to $17.12 during Wednesday trading. Analysts’ consensus rating was Hold, with an average price target of $31.53.
  • MarketBeat previews the top five stocks to own by December 1st.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Deborah Autor sold 23,828 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $18.53, for a total transaction of $441,532.84. Following the transaction, the insider owned 48,961 shares in the company, valued at approximately $907,247.33. The trade was a 32.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Stock Down 2.5%

NYSE:HIMS traded down $0.43 during trading hours on Wednesday, hitting $17.12. 9,531,665 shares of the stock traded hands, compared to its average volume of 22,172,965. The firm has a market cap of $4.01 billion, a price-to-earnings ratio of -20.63 and a beta of 2.53. The firm has a 50 day moving average price of $27.21 and a 200 day moving average price of $26.59. The company has a current ratio of 0.92, a quick ratio of 0.84 and a debt-to-equity ratio of 3.85. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $40.99.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.03). Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. The business had revenue of $890.37 million during the quarter, compared to analysts' expectations of $893.13 million. During the same period in the prior year, the company posted $0.06 earnings per share. The firm's revenue was up 48.6% on a year-over-year basis. Equities research analysts anticipate that Hims & Hers Health, Inc. will post -0.21 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HIMS. Versant Capital Management Inc lifted its holdings in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company's stock worth $26,000 after acquiring an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock worth $27,000 after acquiring an additional 319 shares during the period. GK Wealth Management LLC acquired a new position in Hims & Hers Health in the 3rd quarter worth $37,000. Compass Financial Management LLC acquired a new position in Hims & Hers Health in the 2nd quarter worth $50,000. Finally, Integrated Wealth Concepts LLC bought a new position in Hims & Hers Health during the 2nd quarter worth about $147,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HIMS. Truist Financial increased their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a "hold" rating in a report on Monday, August 24th. Deutsche Bank upped their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a report on Tuesday, August 11th. Barclays reduced their price objective on Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating on the stock in a research note on Friday, August 21st. JPMorgan Chase & Co. initiated coverage on shares of Hims & Hers Health in a research note on Friday, September 11th. They set a "neutral" rating and a $32.00 price target on the stock. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Hims & Hers Health in a research note on Wednesday, November 4th. Three investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $31.53.

Read Our Latest Stock Analysis on HIMS

Hims & Hers Health News Summary

Here's some of the latest news about HIMS:

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Featured Articles

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Hims & Hers Health Right Now?

Before you consider Hims & Hers Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.

While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines